Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2012

Open Access 01-12-2012 | Research article

High dose Erythropoietin increases Brain Tissue Oxygen Tension in Severe Vasospasm after Subarachnoid Hemorrhage

Authors: Raimund Helbok, Ehab Shaker, Ronny Beer, Andreas Chemelli, Martin Sojer, Florian Sohm, Gregor Broessner, Peter Lackner, Monika Beck, Alexandra Zangerle, Bettina Pfausler, Claudius Thome, Erich Schmutzhard

Published in: BMC Neurology | Issue 1/2012

Login to get access

Abstract

Background

Vasospasm-related delayed cerebral ischemia (DCI) significantly impacts on outcome after aneurysmal subarachnoid hemorrhage (SAH). Erythropoietin (EPO) may reduce the severity of cerebral vasospasm and improve outcome, however, underlying mechanisms are incompletely understood. In this study, the authors aimed to investigate the effect of EPO on cerebral metabolism and brain tissue oxygen tension (PbtO2).

Methods

Seven consecutive poor grade SAH patients with multimodal neuromonitoring (MM) received systemic EPO therapy (30.000 IU per day for 3 consecutive days) for severe cerebral vasospasm. Cerebral perfusion pressure (CPP), mean arterial blood pressure (MAP), intracranial pressure (ICP), PbtO2 and brain metabolic changes were analyzed during the next 24 hours after each dose given. Statistical analysis was performed with a mixed effects model.

Results

A total of 22 interventions were analyzed. Median age was 47 years (32–68) and 86 % were female. Three patients (38 %) developed DCI. MAP decreased 2 hours after intervention (P < 0.04) without significantly affecting CPP and ICP. PbtO2 significantly increased over time (P < 0.05) to a maximum of 7 ± 4 mmHg increase 16 hours after infusion. Brain metabolic parameters did not change over time.

Conclusions

EPO increases PbtO2 in poor grade SAH patients with severe cerebral vasospasm. The effect on outcome needs further investigation.
Appendix
Available only for authorised users
Literature
1.
Bederson JB, Connolly ES, Batjer HH, Dacey RG, Dion JE, Diringer MN, Duldner JE, Harbaugh RE, Patel AB, Rosenwasser RH: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009, 40 (3): 994-1025. 10.1161/STROKEAHA.108.191395.CrossRefPubMed
2.
Zhou Y, Martin RD, Zhang JH: Advances in experimental subarachnoid hemorrhage. Acta Neurochir Suppl. 2011, 110 (Pt 1): 15-21.PubMed
3.
Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, et al: Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011, 10 (7): 618-625. 10.1016/S1474-4422(11)70108-9.CrossRefPubMed
4.
Hansen-Schwartz J, Vajkoczy P, Macdonald RL, Pluta RM, Zhang JH: Cerebral vasospasm: looking beyond vasoconstriction. Trends Pharmacol Sci. 2007, 28 (6): 252-256. 10.1016/j.tips.2007.04.002.CrossRefPubMed
5.
Pluta RM: Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005, 105 (1): 23-56. 10.1016/j.pharmthera.2004.10.002.CrossRefPubMed
6.
Ferro JM, Canhao P, Peralta R: Update on subarachnoid haemorrhage. J Neurol. 2008, 255 (4): 465-479. 10.1007/s00415-008-0606-3.CrossRefPubMed
7.
Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ: Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg. 2009, 111 (1): 171-180. 10.3171/2009.3.JNS081332.CrossRefPubMed
8.
Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV: Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien). 2007, 149 (11): 1089-1101. 10.1007/s00701-007-1284-z. discussion 1101CrossRef
9.
Turner JD, Mammis A, Prestigiacomo CJ: Erythropoietin for the treatment of subarachnoid hemorrhage: a review. World Neurosurg. 2010, 73 (5): 500-507. 10.1016/j.wneu.2010.02.026.CrossRefPubMed
10.
Xiong Y, Chopp M, Lee CP: Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury. Neurol Res. 2009, 31 (5): 496-502. 10.1179/174313208X353703.CrossRefPubMed
11.
Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999, 19 (6): 643-651.CrossRefPubMed
12.
Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R: Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun. 1998, 253 (1): 26-32. 10.1006/bbrc.1998.9748.CrossRefPubMed
13.
14.
15.
Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T, Nilsson M, Howells DW: A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab. 2010, 30 (5): 961-968. 10.1038/jcbfm.2009.267.CrossRefPubMed
16.
Contaldo C, Elsherbiny A, Lindenblatt N, Plock JA, Trentz O, Giovanoli P, Menger MD, Wanner GA: Erythropoietin enhances oxygenation in critically perfused tissue through modulation of nitric oxide synthase. Shock. 2009, 31 (6): 599-606.CrossRefPubMed
17.
Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS: Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 2005, 36 (12): 2731-2737. 10.1161/01.STR.0000190021.85035.5b.CrossRefPubMed
18.
Murphy AM, Xenocostas A, Pakkiri P, Lee TY: Hemodynamic effects of recombinant human erythropoietin on the central nervous system after subarachnoid hemorrhage: reduction of microcirculatory impairment and functional deficits in a rabbit model. J Neurosurg. 2008, 109 (6): 1155-1164. 10.3171/JNS.2008.109.12.1155.CrossRefPubMed
19.
Jaeger M, Soehle M, Schuhmann MU, Winkler D, Meixensberger J: Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen. Acta Neurochir (Wien). 2005, 147 (1): 51-56. 10.1007/s00701-004-0408-z. discussion 56CrossRef
20.
Wang L, Zhang Z, Wang Y, Zhang R, Chopp M: Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004, 35 (7): 1732-1737. 10.1161/01.STR.0000132196.49028.a4.CrossRefPubMed
21.
Marti HH, Bernaudin M, Petit E, Bauer C: Neuroprotection and Angiogenesis: Dual Role of Erythropoietin in Brain Ischemia. News Physiol Sci. 2000, 15: 225-229.PubMed
22.
Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muia C, Crisafulli C, Caputi AP, Thiemermann C: Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med. 2006, 34 (4): 1168-1177. 10.1097/01.CCM.0000207346.56477.E8.CrossRefPubMed
23.
Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin NA, Glenn TC, McArthur DL, Hovda DA: Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab. 2005, 25 (6): 763-774. 10.1038/sj.jcbfm.9600073.CrossRefPubMedPubMedCentral
24.
Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, et al: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007, 357 (10): 965-976. 10.1056/NEJMoa071533.CrossRefPubMed
25.
Springborg JB, Ma X, Rochat P, Knudsen GM, Amtorp O, Paulson OB, Juhler M, Olsen NV: A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol. 2002, 135 (3): 823-829. 10.1038/sj.bjp.0704521.CrossRefPubMedPubMedCentral
Metadata
Title
High dose Erythropoietin increases Brain Tissue Oxygen Tension in Severe Vasospasm after Subarachnoid Hemorrhage
Authors
Raimund Helbok
Ehab Shaker
Ronny Beer
Andreas Chemelli
Martin Sojer
Florian Sohm
Gregor Broessner
Peter Lackner
Monika Beck
Alexandra Zangerle
Bettina Pfausler
Claudius Thome
Erich Schmutzhard
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2012
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-12-32

Other articles of this Issue 1/2012

BMC Neurology 1/2012 Go to the issue

Study protocol

Protocol for a home-based integrated physical therapy program to reduce falls and improve mobility in people with Parkinson’s disease

Research article

Usability of therapy controllers in elderly patients with deep brain stimulation

Correspondence

Brief International Cognitive Assessment for MS (BICAMS): international standards for validation

Research article

Effects of cardiovascular exercise early after stroke: systematic review and meta-analysis

Research article

Health-related quality of life and strain in caregivers of Australians with Parkinson’s disease: An observational study

Review

Clinical correlates of grey matter pathology in multiple sclerosis